Kenya Receives Grant for Free HIV Prevention Injections

Kenya has received a Sh256 million ($2 million) grant from the Global Fund to support the nationwide distribution of Lenacapavir, a new HIV prevention injection. The initiative, launched in Nairobi, represents a shift from daily oral medication to a twice-yearly injectable.

Lenacapavir Implementation

The grant will focus on service delivery, healthcare worker training, and community engagement in 15 high-burden counties. Lenacapavir functions by creating a depot in the body that slowly releases medication over six months, unlike oral PrEP which requires daily adherence.

Addressing Prevention Challenges

Recent data indicates a shortage of condoms, contributing to increased STI and HIV infections. Young women and adolescent girls are disproportionately affected by new HIV transmissions in Kenya. The rollout of Lenacapavir will prioritize individuals who experience stigma related to daily oral medication.

Important Considerations

The Ministry of Health emphasizes that Lenacapavir does not protect against other sexually transmitted infections or prevent unintended pregnancies. Public health campaigns are being revised to incorporate comprehensive sexual reproductive health education alongside the introduction of the injection.

Long-Term Sustainability

While the Global Fund’s grant provides immediate support, securing long-term sustainability is a priority. The government is working to establish bilateral agreements with pharmaceutical companies to reduce the drug’s procurement cost as donor funding decreases. Successful management of the program could lead to a significant reduction in new HIV infections within the next decade.